Tasly Pharmaceutical Group Past Earnings Performance
Past criteria checks 4/6
Tasly Pharmaceutical Group's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 21.5% per year. Tasly Pharmaceutical Group's return on equity is 8.1%, and it has net margins of 12.8%.
Key information
-9.0%
Earnings growth rate
-8.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -21.5% |
| Return on equity | 8.1% |
| Net Margin | 12.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Tasly Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 8,638 | 1,102 | 3,344 | 951 |
| 31 Dec 23 | 8,674 | 1,071 | 3,334 | 917 |
| 30 Sep 23 | 9,032 | 1,120 | 3,354 | 812 |
| 30 Jun 23 | 8,951 | 867 | 3,394 | 730 |
| 31 Mar 23 | 8,798 | 567 | 3,292 | 873 |
| 31 Dec 22 | 8,637 | -264 | 3,266 | 845 |
| 30 Sep 22 | 8,315 | 534 | 3,477 | 774 |
| 30 Jun 22 | 8,159 | 940 | 3,389 | 789 |
| 31 Mar 22 | 8,063 | 1,478 | 3,381 | 584 |
| 31 Dec 21 | 7,952 | 2,359 | 3,337 | 580 |
| 30 Sep 21 | 7,955 | 1,507 | 3,494 | 727 |
| 30 Jun 21 | 8,779 | 1,442 | 3,387 | 711 |
| 31 Mar 21 | 11,387 | 1,154 | 3,323 | 724 |
| 31 Dec 20 | 13,576 | 1,126 | 3,280 | 689 |
| 30 Sep 20 | 16,298 | 969 | 3,132 | 529 |
| 30 Jun 20 | 18,205 | 789 | 3,232 | 530 |
| 31 Mar 20 | 18,380 | 848 | 3,251 | 522 |
| 31 Dec 19 | 18,998 | 1,001 | 3,404 | 551 |
| 30 Sep 19 | 19,057 | 1,308 | 3,524 | 579 |
| 30 Jun 19 | 18,931 | 1,519 | 3,497 | 602 |
| 31 Mar 19 | 18,609 | 1,622 | 3,492 | 603 |
| 31 Dec 18 | 17,990 | 1,545 | 3,360 | 592 |
| 30 Sep 18 | 17,957 | 1,607 | 3,547 | 570 |
| 30 Jun 18 | 17,306 | 1,545 | 3,201 | 752 |
| 31 Mar 18 | 16,699 | 1,430 | 3,164 | 622 |
| 31 Dec 17 | 16,094 | 1,377 | 3,102 | 506 |
| 30 Sep 17 | 15,497 | 1,312 | 3,120 | 331 |
| 30 Jun 17 | 14,811 | 1,248 | 3,293 | 0 |
| 31 Mar 17 | 14,148 | 1,218 | 3,251 | 0 |
| 31 Dec 16 | 13,945 | 1,176 | 3,214 | 0 |
| 30 Sep 16 | 13,454 | 1,263 | 2,802 | 0 |
| 30 Jun 16 | 13,391 | 1,333 | 2,841 | 0 |
| 31 Mar 16 | 13,294 | 1,410 | 2,777 | 0 |
| 31 Dec 15 | 13,228 | 1,479 | 2,948 | 0 |
| 30 Sep 15 | 12,742 | 1,447 | 2,721 | 0 |
| 30 Jun 15 | 12,698 | 1,454 | 2,706 | 0 |
| 31 Mar 15 | 12,640 | 1,429 | 2,608 | 0 |
| 31 Dec 14 | 12,578 | 1,368 | 2,548 | 0 |
| 30 Sep 14 | 12,234 | 1,335 | 2,501 | 0 |
| 30 Jun 14 | 11,816 | 1,242 | 2,412 | 0 |
| 31 Mar 14 | 11,394 | 1,138 | 2,462 | 0 |
| 31 Dec 13 | 11,108 | 1,098 | 2,367 | 0 |
| 30 Sep 13 | 10,942 | 1,060 | 2,211 | 0 |
| 30 Jun 13 | 10,554 | 1,005 | 2,132 | 0 |
Quality Earnings: 600535 has high quality earnings.
Growing Profit Margin: 600535's current net profit margins (12.8%) are higher than last year (6.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600535's earnings have declined by 9% per year over the past 5 years.
Accelerating Growth: 600535's earnings growth over the past year (94.2%) exceeds its 5-year average (-9% per year).
Earnings vs Industry: 600535 earnings growth over the past year (94.2%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 600535's Return on Equity (8.1%) is considered low.